NCT05636605Recruiting
Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
Source: ClinicalTrials.gov · Last updated 20 Dec 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The investigators plan to conduct a multiomics analysis（such as, Genomics, proteomics, single cell RNA sequencing, space transcriptomics）of tumor tissue and blood, aiming at analyzing tumor heterogeneity, mapping the microenvironment map of lung cancer and exploring the mechanism of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 24 Nov 2022
- Start date
- 1 Jan 2018
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Diseases
- Lung cancer
- NCT number
- NCT05636605
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Jan 2018 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently participating in interventional clinical research treatment, or received other research drugs or used research devices within 4 weeks before the first administration
- The study was receiving systemic glucocorticoid treatment (excluding local glucocorticoids by nasal spray, inhalation or other means) or any other form of immunosuppressive therapy within 7 days before the first administration; Note: It is allowed to use glucocorticoid with physiological dose (prednisone ≤ 10mg/day or equivalent)
Other illness
- Within 5 years or at the same time, there are other active malignancies
- Active autoimmune diseases requiring systemic treatment (such as the use of disease relieving drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administration
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Who the study is looking for
- Histopathology or hemology diagnostics of lung cancer
- Patients have never received any antineoplastic therapy
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Fourth Affiliated Hospital of Zhejiang University Coordinator of this site? Confirm its status | Yiwu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.